Table 1

Baseline demographics, disease characteristics, and changes after the 8-week treatment

Once weekly
Once every 2 weeks
Placebo5 mg10 mg20 mg10 mg20 mg
n49*50*49*50*50*49*
Sex (female/male)57/4348/5239/6164/3648/5255/45
Age (years)56 ± 657 ± 756 ± 856 ± 853 ± 1156 ± 7
BMI (kg/m2)31.8 ± 4.933.2 ± 5.332.6 ± 4.732.4 ± 5.233.1 ± 5.133.2 ± 5.1
Duration of diabetes (years)5 ± 46 ± 65 ± 55 ± 45 ± 46 ± 5
Metformin dose (mg/day)2,019 ± 631,897 ± 511,888 ± 531,998 ± 572,011 ± 681,934 ± 56
Systolic blood pressure (mmHg)129 ± 13127 ± 13128 ± 14131 ± 14132 ± 13132 ± 13
Diastolic blood pressure (mmHg)77 ± 978 ± 878 ± 880 ± 981 ± 881 ± 7
A1C (%)8.0 ± 0.17.9 ± 0.17.9 ± 0.17.8 ± 0.18.0 ± 0.17.9 ± 0.1
    Δ−0.2−1.0−1.2−1.2−0.9−1.0
    P<0.0001<0.0001<0.0001<0.0001<0.0001
Fructosamine (μmol/l)310 ± 6310 ± 6300 ± 6292 ± 6309 ± 6−290 ± 6
    Δ−5 ± 4−44 ± 4−51 ± 4−48 ± 4−35 ± 4−40 ± 4
    P<0.0001<0.0001<0.0001<0.0001<0.0001
Fasting glucose (mg/dl)173 ± 5187 ± 5175 ± 5164 ± 5175 ± 5171 ± 5
    Δ−14−33−45−45−22−26
    P0.0002<0.0001<0.00010.130.02
Proinsulin-to-insulin ratio0.590 ± 0.0320.579 ± 0.0320.594 ± 0.0320.550 ± 0.0320.606 ± 0.0310.613 ± 0.032
    Δ0.002−0.079−0.120−0.166−0.091−0.055
    P0.07380.00760.00030.03720.2054
Lipid parameters
    Total cholesterol (mg/dl)211 ± 6201 ± 6195 ± 6194 ± 6196 ± 6200 ± 6
        Δ+7−8−12−9−7−12
    LDL cholesterol (mg/dl)127 ± 5117 ± 5116 ± 5113 ± 5114 ± 5114 ± 5
        Δ+5−3−8+1−0−6
    HDL cholesterol (mg/dl)47 ± 245 ± 245 ± 245 ± 244 ± 243 ± 2
        Δ+0−1−2−1−10
    Triglycerides (mg/dl)224 ± 27220 ± 27188 ± 28199 ± 27220 ± 27256 ± 27
        Δ+9−22−26−48−28−27
  • Data are means ± SD for baseline characteristics and mean ± SEM for disease characteristics.